还原型谷胱甘肽改善化疗致肝功能损害的临床研究

目的探讨还原型谷胱甘肽（GSH）注射液对化疗致肝损害的改善作用。方法采用临床对照试验,将40例诊断明确且排除肝脏转移性癌及原发性肝癌的恶性肿瘤患者随机分为两组,每组20例。治疗组在化疗同时及结束后给予还原型谷胱甘肽1.8 g/天,静滴;对照组给予肌苷注射液0.4 g/天、维生素C 2 g/天,静滴;连用7天后复查肝功能。结果治疗组化疗前后相比较,肝功能各项指标化疗前后无明显差异（P〉0.05）;对照组化疗前后相比较,谷丙转氨酶、谷草转氨酶、碱性磷酸酶均化疗前升高,且有统计学差异（P〈0.05）。化疗前,治疗组与对照组相比,肝功能各项指标无明显差异（P〉0.05）;化疗后,治疗组与对照组相比,谷丙转氨酶、谷草转氨酶、碱性磷酸酶均较低,且有统计学差异（P〈0.05）。结论还原型谷胱甘肽对恶性肿瘤患者化疗药物性肝损害有较好的防治作用,且不影响化疗效果。

A clinical study onreduced glutathione alleviating chemotherapyinduced liver impairment

Objective To evaluate the effect of reduced glutathione （GSH） in alleviating liver impairment eansed by chemotherapentics. Methods Forty patients diagnosed of malignant cancer, primary liver cancer and metastatic liver cancer were excluded, were randomly divided into two groups - control group and GSH group. Each group included twenty patients. In GSH group, patients received intravenous drip of GSH （ 1.8 g/ day） during and after chemotherapy. Patients in control group received intravenous drip of creatinine （0.4 g/ day） and vitamin C （2 g/day）. Liver functions were re - examined 7 days later. Results In GSH group,liver functionwas not obviously changed after chemotherapy, however, the levels of ALT, AST and ALP in control groupwere significantly increased after chemotherapy （ P 〈 0. 05 ）. Besides, after chemotherapy, the levels of ALT, AST and ALP in GSH group were significantly lower than those in control group （P 〈 0. 05）. Conclusions Reduced GSH could effectively prevent chemotherapy - induced Dver impairment form occurring, but without counteracting the curative effect.